There is very much a multi-disciplinary team (MDT) approach to treating Neuroendocrine Tumours (NET) in Europe and many other places. In Europe and the extra-Europe CoEs in Australia, Israel and the USA, this is centred on the establishment of the Centre of Excellence programme that has been running since 2009. But underneath that are some excellent MDTs not yet accredited who may still utilise ENETs guidelines to treat and manage their patients.
This 2023 guideline paper sets the scene for an important and complex group of tumours – pancreatic NETs. It’s well known and accepted that the majority of pancreatic NETs are non-functional, depending on where you look, anything between 50 and 85%. “Non-functional” means that the tumour doesn’t produce a sufficient set of symptoms to cause a hormonal syndrome.
While the diagnosis of functionality relies on the presence of a hormonal syndrome, the NET-diagnosis continues to rely on histological or cytological analysis. There is a separate guidance paper on functional pancreatic NETs – click here to read that.
Prior to 2022/23, the most recent and comprehensive set of guidelines were based on the 2016 series which were behind a subscription wall. I have had access to those via my ENETS membership and quoted them many times in my patient group and citing them in my spotlight on NENs series. I am very pleased to see many of the 2022/23 guidance papers made public and am happy to share with you via my blog.
This ENETS guidance paper for well-differentiated non-functioning pancreatic neuroendocrine tumours (NF-Pan-NET) has been developed by a multidisciplinary working group and provides up-to-date and practical advice on the management of these tumours.
Using the extensive experience of centres treating patients with NF-Pan-NEN, the authors of this guidance paper discuss 10 troublesome questions in everyday clinical practice. Our many years of experience in this field are still being verified in the light of the results of new clinical, which set new ways of proceeding in NEN. The treatment of NF-Pan-NEN still requires a decision of a multidisciplinary team of specialists in the field of neuroendocrine neoplasms.
I see from watching exchanges between ENET specialists and other regions (North America etc), I see there is a wide consensus to be found in each other’s guidelines and recommendations. I also note they both attend each other’s annual conferences, listening, contributing and presenting. This has to be a good thing for patients. Nonetheless, those not being treated in ENETS Centres of Excellence or associated MDTs, should refer to their own regional guidelines.
See Table 1 below on the management of these neoplasms
TABLE 1. Ten major questions on management of non-functioning pancreatic neuroendocrine tumours.
- How should we define and characterise a NF-Pan-NET patient at clinical presentation?
- Which biochemical tests should be performed in a patient with NF-Pan-NET?
- Which is the most suitable imaging work-up for NF-Pan-NET patients?
- What is the appropriate surgical management of NF-Pan-NET?
- What is the role of PRRT in patients with NF-Pan-NET?
- What is the role of biotherapy and molecular targeted therapies in patients with advanced NF-Pan-NET?
- What is the role of chemotherapy in patients with advanced NF-Pan-NET?
- In the setting of advanced disease, which is the most suitable first-line systemic therapy? Which sequence of treatments should be used?
- Is there a specific work-up in MEN1-associated NF-Pan-NET patients?
- What is the recommended follow-up in NF-Pan-NET patients?
Now read the reference material below
Reference
Click on the blue link below see read the discussion and the recommendations for each of those questions.
European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours
Beata Kos-Kudła, Justo P. Castaño, Timm Denecke, Enrique Grande, Andreas Kjaer, Anna Koumarianou, Louis de Mestier, Stefano Partelli, Aurel Perren, Stefan Stättner, Juan W. Valle, Nicola Fazio
First published: 05 October 2023https://doi.org/10.1111/jne.13343
More Guidelines
Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Click here and answer all questions to join my private Facebook group
- Don’t miss these 5 posts on RonnyAllan.NET
Just click on the pictures and read (and hopefully share!) Disclaimer I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or… Read more: Don’t miss these 5 posts on RonnyAllan.NET - Ronny Allan’s Newsletter covering October 2026
Summary of October 2026 on RonnyAllan.NET October was similar to the other months of this year but like July and August, views are down on the previous two months due to 3 weeks of holiday. Still a reasonable blog performance – I can’t complain. Still managed to cover 3 new US FDA approvals! I had… Read more: Ronny Allan’s Newsletter covering October 2026 - I made it to 71!
I started doing the “Piss off cancer” or “I made it” series when I got to 65, mainly because I initially thought I wouldn’t make that age. I was 54 years and 9 months old at diagnosis on 26th July 2010. For the first few months, I had no idea what the outcome would be. … Read more: I made it to 71! - Neuroendocrine Tumours (NET) – Does rising incidence and prevalence need more research, funding and resources?
The title of this blog is the form of a rhetorical question. Neuroendocrine Tumours (NET) – Does rising incidence and prevalence need more research, funding and resources? I guess if you ask any patient, the answer is a resounding YES. I also very much guess that many doctors would repeat that answer. And some are… Read more: Neuroendocrine Tumours (NET) – Does rising incidence and prevalence need more research, funding and resources? - Ronny Allan’s Newsletter covering September 2026
Summary of September 2026 on RonnyAllan.NET September was similar to the other months of this year but like July and August, views are down on the previous two months due to 3 weeks of holiday. Still a reasonable blog performance – I can’t complain. Still managed to cover 3 new US FDA approvals! I had… Read more: Ronny Allan’s Newsletter covering September 2026 - Amneal Lanreotide Approved by US FDA
Amneal launches first CGT‑designated U.S. generic lanreotide — what NET patients need to know Amneal has launched the first Competitive Generic Therapy (CGT)‑designated U.S. generic for lanreotide, a major milestone in a market long dominated by Ipsen’s Somatuline® Depot. The product — lanreotide injection 120 mg/0.5 mL in a sterile single‑dose prefilled syringe —… Read more: Amneal Lanreotide Approved by US FDA - Ronny Allan’s Newsletter covering August 2026
Summary of August 2026 on RonnyAllan.NET August was similar to the other months of this year but like July, views are down on the previous two months due to 50% of the month spent on holiday. Still a reasonable blog performance – I can’t complain. Other key targets met were three more editions of the Spotlight… Read more: Ronny Allan’s Newsletter covering August 2026 - External Beam Radiation Therapy (EBRT) for Neuroendocrine Neoplasms
Disclaimer: The information in this section is for education only and does not represent a standard care pathway or service. These treatments are not suitable for everyone, and careful patient selection by an experienced multidisciplinary team is essential. Always discuss your individual situation with your own specialist team. External Beam Radiation Therapy (EBRT) is… Read more: External Beam Radiation Therapy (EBRT) for Neuroendocrine Neoplasms - 2026 Surveillance Update from Ronny Allan: “See you in 12 months”
It’s only a couple of weeks since I celebrated my 16th year since diagnosis of metastatic small intestine Neuroendocrine Tumour (NET) at Grade 2 on 26th July 2010. Thinking back to that period of my life, I’m happy but also slightly amazed to be celebrating such a long milestone having been diagnosed with cancer at… Read more: 2026 Surveillance Update from Ronny Allan: “See you in 12 months” - Spotlight: Selenium in Neuroendocrine Tumours (NETs)
Before you read this This information is designed to help you understand how vitamins and minerals work in the body and how certain NET‑related factors might influence them. It is not a substitute for personalised medical advice. Every NET patient is different — tumour type, treatments, surgery, symptoms, and nutritional needs vary widely. If you… Read more: Spotlight: Selenium in Neuroendocrine Tumours (NETs)
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts sent to your email.
Maybe I just missing something here but what are the resulting recommendations for the ten points?
In the citation link